TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma February 22, 2013
TCL Archive Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials. December 2, 2005
